U.S. Exosome-based Therapy Market Driven by Biotech and Personalized Medicine Trends

The U.S. exosome-based therapy market size accounted for USD 15.61 million in 2024 and is predicted to touch around USD 79.67 million by 2034, growing at a CAGR of 17.7% from 2025 to 2034. Rising prevalence of cancers due to a higher number of carcinogens and endocrine disruptors in consumer daily use, increasing government and non-government initiatives for exosome research, increasing investment in biotechnology and personalized medicines, and rising technological advancements in exosome isolation, especially with extracellular vesicles, are driving the growth of the U.S. exosome-based therapy market.

U.S. Exosome-based Therapy Market Highlights

• By therapy type, the exosome therapeutics segment underwent notable growth in the U.S. exosome-based therapy market during 2024.
• By therapy type, the exosome isolation and engineering segment is expected to grow at the fastest rate during the forecast period of 2025 to 2034.

Industry Valuation and Growth Rate Projection

The U.S. exosome-based therapy market refers to the production, distribution, and application of exosome-based therapy has shown promise in many medical applications, including cancer treatment, immune modulation, and tissue repair. Extracellular vesicles in circulation carry both proteins and genetic material from their origin cell, proteo-transcriptomic signatures that act as biomarkers. Exosome therapy is becoming increasingly popular due to its anti-aging and skin rejuvenation benefits. Exosomes can speed up hair growth, as well as enhance skin health by promoting collagen synthesis, minimizing inflammation, and improving skin texture and elasticity. Exosome-based therapy benefits also include promoting cardiovascular health, holds the potential for cancer treatment, neuroprotection and neurogeneration, anti-inflammatory effects, and improved tissue repair and regeneration.

Rising interest in exosome-based skincare and cosmetics, growing applications in drug delivery and regenerative medicine, innovation in exosome isolation and purification technologies, and rising demand for exosome-based diagnostics are driving the growth of the U.S. exosome-based therapy market.

• According to a report published in August 2023, Worldwide, 3 of 5 people die due to chronic inflammatory diseases like diabetes, obesity, cancer, heart disorders, chronic respiratory diseases, and stroke.

U.S. Exosome-based Therapy: Stats and Figures

• According to a study published by Rezaie J et al. in 2022, there were 116 registered clinical trials evaluating exosomes; 2 as cancer vaccines, 6 for drug delivery, 33 as cell-free
• therapeutic agents, 58 as biomarkers, and 17 basic analysis studies for determining exosome kinetics. The clinical applications in these studies cross many indications, including cancer, osteoarthritis, neuralgia, and Alzheimer’s disease.
• According to the statistical data published by Xia & He Publishing Inc., the incidence of this tumor is 3.21 per 100000 people in the United States, making it the most frequent primary brain tumor.

How Has AI Benefited the U.S. Exosome-Based Therapy Market?

Artificial intelligence (AI) use in exosome therapy is its ability to help identify the best cells for a particular patient. By analyzing patient outcomes and behavior data, AI algorithms can provide insights into enhancing education interventions and identify areas where education is ineffective or lacking. AI allows the development of predictive models by analyzing patient data, like metabolomics, genomics, and proteomics. AI benefits include its versatility, ability to enhance the efficiency of the inward budding of a late endosome. , automate processes, and generate insights across industries. AI boosts productivity, improves service productivity, ensures 24/7 reliability, improves user experience, reduces operational costs, minimizes human errors, accelerates digital presence, and improves decision making.

• In January 2025, a startup to transform targeted drug delivery using milk exosomes- natural nanoparticles that contain milk to transport cargo to human cells was launched by two Nebraska researchers, Janos Zemplini and Jiantao Guo.

U.S. Exosome-Based Therapy Market Dynamics

Drivers

Exosomes Addressing Rising Cancer Rates Through Biomarker Innovation

Rising prevalence of cancer: The rate of cancer is increasing due to a vicious circle of obesity, highly processed foods, environmental pollution, exposure to harmful chemicals, insecticides, industrial pollution, and sedentary lifestyles. In terms of cancer, exosomes play an important role as mediators of intracellular communication, leading to tumor progression. Additionally, they can act as biomarkers for cancer detection and progression. Exosomes can carry molecules representative of the original cell, including cancer cells. Early cancer detection is made possible by analyzing exosomal content when the cancer cells release the exosomes into the bloodstream or other biofluids.

• According to a report published in February 2024 by the World Health Organization (WHO), in 2022, 20 million new cancer cases were estimated, along with 9.7 million deaths. The estimated number of people who were still within 5 years of a cancer diagnosis came in at 53.5 million. About 5 in 1 people are expected to develop cancer in their lifetime, and with 1 in 9 males and 1 in 12 females expected to succumb to the disease.

Rising technological advancements in exosome isolation: A series of technological advancements that can aid in harnessing endogenous exosomes. V-Tech Exomes treatment is an advanced skin rejuvenation therapy designed to target signs of aging at a cellular level. It works by delivering active ingredients like plant stem cells, peptides, and polynucleotides directly to skin cells via synthetic exosomes. Recent studies show microphage-based exosomes, as an extracellular vehicle, can deliver diverse cargoes, including nanoparticles, small molecules, and biological macromolecules, towards recipient cells, and thus affect the progression of cancers and other diseases.

• In October 2024, an advanced exosome-based skin and hair rejuvenation treatment in Bengaluru was launched by Dr. Karishma Kagodu, a plastic and cosmetic surgeon, and the founder of Dr. Karishma Asthetics.

Restraints

Challenges in Ethical Practices and Standardization of Exosome Therapies

• Ethical and privacy concerns: The disadvantages of ethical and privacy concerns include not being suitable for small businesses, a lack of profit maximization, profitability is restricted, instability, consuming time, improving companies’ reputation, reduced profits with ethical practices, and the significance of ethical conduct. Too much privacy can fail to exchange ideas and to learn from others. And when third parties gain access to our private information, it may risk of data loss, regulatory fines, and reputational damage. Ethical issues in business occur when a decision or activity conflicts with the organization's or society’s ethical standards.
• Lack of standardization: Lack of adequate standardization practices can lead to a lack of uniformity and inconsistent in services and quality, making it difficult to measure and compare performance for comparison across different units. Additionally, a lack of consistency can make it difficult for employees to move between business units due to they may need to learn new processes and procedures. Applying uniform standards to different projects can be inefficient due to each project may have its own unique needs. This standardization deficit can slow the growth of a technology or industry due to potential customers hesitating to commit to competing formats and approaches.

Opportunity

Accelerating Role of Research–Pharma Collaborations in Driving Commercialization

• Increasing collaboration between research institutes and pharmaceutical companies: The increasing knowledge trading and cooperation between research institutes and pharmaceutical companies are expected to accelerate commercialization. One of the primary benefits of collaboration is the shared knowledge and expertise it provides. Scientists can avoid working in closed loops and instead build on existing research, databases, and interdisciplinary research. With advances in nanotechnologies, an interdisciplinary approach will lead to breakthroughs. By collaborating with institutions and researchers worldwide, universities can be exposed to diverse pools of knowledge and expertise. The global exchange of ideas leads to more innovative, impactful, and comprehensive research outcomes.

Industry Leader Announcements

• Rich McCartney, president of chemical analysis at Thermo Fischer Scientific

Rich McCartney, president of chemical analysis at Thermo Fischer Scientific, said, “We are honored to work with the U.S. Navy to help safeguard the health and safety of their personnel.” “This contract underscores the Navy’s trust in our ability to deliver cutting-edge dosimetry technology and data management solutions. Our next-generation systems are purpose-built to provide precise, real-time radiation monitoring in the most demanding environments.”

Segmental Insights

The exosome therapeutics segment underwent notable growth in the U.S. exosome-based therapy market during 2024 and is expected to grow at the fastest rate during the forecast period of 2025 to 2034. Exosome therapy is an effective tool that combats signs of aging. It repairs and regenerates damaged skin cells and promotes youthful and radiant skin. Exosome therapy regenerates healthier cells and repairs damaged cells. The re-energized cells function better, which helps in boosting the body’s overall immunity, making us less prone to falling ill. Exosomes can carry and exchange many cargos between cells and are used as a non-invasive biomarker for many diseases. Exosomes are considered the best biomarker for cancer diagnosis, owing to their unique characteristics. We can apply exosome-containing products daily. In regenerative medicine, exosomes facilitate tissue repair and regeneration. Exosome therapy boosts regeneration, improves structure, and reduces wrinkles by stimulating collagen production.

The exosome isolation and engineering segment is expected to grow significantly during the forecast period. Isolating exosomes from serum offers many benefits, like providing valuable insights into disease diagnostics and biomarker discovery, because of the rich content of lipids, proteins, and RNA that reflects the physiological state of their cells of origin. Exosome engineering involves the manipulation of exosomes to improve their functionality by loading specific cargo or modifying their surface. Several methods, including physical, biological, and chemical techniques, are employed for creating advanced exosomes. Exosome engineering can improve their targeting capability, providing potential wide clinical applications for treating diseases, including bone defects.

Recent Developments in the U.S. Exosome-based Therapy Market

• In May 2025, the grand opening of the second clinic at Vasant Vihar, Delhi, was announced by the PRIVE LUX Skin and Wellness Clinic, the luxury wellness space founded by celebrated dermatologists and cosmetologists Dr. Amit Bhasin and Dr. Aarti Bhasin. The new clinic introduces India’s first authentic Korean PDRN + Exosome Therapy, a regenerative treatment that is rapidly gaining popularity across Asia for its ability to heal damaged skin, improve texture, and deeply hydrate at a cellular level.
• In March 2025, an important milestone was achieved by conducting the world’s first human application of small extracellular vesicles (sEV), also called exosomes, for osteoarthritis (OA)-EVA-100 was achieved by a U.S.-based clinical-stage biotech company, EVast Bio. According to a recent study published in the Journal of Nanobiotechnology, this achievement demonstrates promising results in inflammation control and cartilage protection, which offers a new therapeutic option for millions of patients suffering from OA.
• In June 2024, the exosome therapy with microneedling in Ontario was launched by a leading and trusted name in medical aesthetics across Ontario, Canada, MedLaser Clinics. This invasive, advanced, regenerative skincare solution is now available at all clinic locations, ushering in a new era of natural skin rejuvenation and repair.
• In October 2024, the initiation of a clinical study to assess the efficacy of Elevai’s topical exosome product in conjunction with an energy device treatment on facial skin appearance was announced by a pioneering force in medical aesthetics, Elevai Labs, Inc. The clinical study will assess the efficacy of Elevai’s topical exosomes Elevai empower, a topical exosome serum designed specifically for in-office application, and Elevai enfinity, a daily topical exosome product for at-home use, as standalone treatments and in conjunction with an energy device treatment on facial skin appearance.

Competitive Landscape

• Company Name: Thermo Fischer Scientific, Inc.
• Year of Incorporation: 2006
• Headquarters: Waltham, Massachusetts, United States

Over 50 countries where it operates. It operates in the biopharma services, laboratory products, specialty diagnostics, analytical instruments, and life sciences solutions sectors around the world.

• Company Name: Bio-Techne Corp
• Year of Incorporation: 1976
• Headquarters: Minneapolis, Minnesota, United States

It operates in over 20 countries. It operates in the biotechnology sector, especially in the healthcare industry, around the world.

• Company Name: QIAGEN
• Year of Incorporation: 1984
• Headquarters: Hilden, Germany

Over 25 countries where it operates. It operates in the molecular diagnostics and life sciences sectors around the world.